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Is Neurohormonal Activation Me' er; , _is to the Long-Term Outcome
of Patients With Congestive Heart Failure?
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Any objective assessment of the long-term outcome of
patients with congestive heart failure should be based on two
principal criteria: 1) what is the life expectancy of these
patients
; and 2) what are the clinical course and fur,etional
capacity of these patients during the period of follow-up? At
first glance, these questions would appear to be inextricably
interrelated, but during the last several years we have
learned that the factors that determine a patient's symptoms
may not be similar to those that determine the duration of
survival . Although both left ventricular function and exer-
cise tolerance are excellent predictors of survival (14),
there may be little relation between indexes of cardiac
performance and functional capacity in patients with heart
failure (5)
. Hence, the determinants of morbidity and mor-
tality in chronic heart failure must be assessed separately,
especially when we evaluate the impact of therapeutic
interventions in this disease .
What is responsible for this discordance between the
severity ofcardiac dysfunction
and the clinical presentation
of patients with chronic heart failure? There is growing
evidence (6) that peripheral responses in heart failure, such
as changes in regional blood flow, peripheral organ function
and neurohormonal acti Ay, vary considerably among indi-
viduals with the same degree of cardiac dysfunction . Yet, we
do not know whether these peripheral responses are primar-
ily markers of the severity of the underlying disease or
whether they contribute directly to the poor outcome of
there patients . We can begin to formulate a respoase to this
question by comparing the long-term impact of therapeutic
interventions that differ in their effects on neurohormonal
systems and, perhaps, an peripheral organ, flow and func-
tion. If we can show that neurohormonal antagonists (such
as converting enzyme inhibitors and beta-adrenergic black-
ing agents) are more effective than direct-acting vasodilators
(which often activate rather than suppress the neurohormo-
nal systems) in modifying the clinical course of patients with
heart failure, then we can hypothesize that neurohormonal
activity exerts a direct deleterious effect on the long-term
outcome of these severely ill patients .
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Survival of
Patients With Chronic Congestive
Heart Failure
Patients with congestive heart failure have an extremely
poor long-term prognosis ; the annual mortality rate in this
disease varies from 10 to 50% depending on its clinical
severity and mode of presentation (2) . Three patterns of
death can usually be discerned: 1) sudden, unexpected
death, occurring in approximately 40% of patients ; 2) pro-
gressive, worsening heart failure accompanied by evidence
of deteriorating cardiac and peripheral organ function, oc-
curring in about 40%; and 3) new cardiovascular orintercur-
rent events (such as myocardial infarction, pulmonary or
arterial emboli or pneumonia), occurring in approximately
20% of patients.
Prediction of long-taren prognosis. A number of factors
that can be measured in patients with chronic heart failure
appear to identify patients at high and low risk of death
: 1)
symptoms ; 2) cardiac function; 3) exercise capacity; 4)
ventricular arrhythmias; and 5) neurohormonal activity .
Patients with severe symptoms of heart failure (New
York Heart Association functional class IV) have a I year
mortality rate exceeding 50%, whereas those with milder
symptoms have an annual mortality rate of only 10 to 20%0 .
More importantly, patients who present with progressive
symptoms have a much poorer prognosis than do those who
are clinically stable (7), perhaps because cardiac function is
rapidly deteriorating in these patients or because cardiovas-
cular homeostasis can only be achieved at a price that is
associated with high risk
. Once symptoms are well estab-
lished, the underlying cause does not appear to have prog-
nostic importance
. Patients with a recent myocardial infarc-
tion have a particularly poor short-term outlook because of
their propensity for recurrent ischemic events, but after 6
months, the prognosis in such individuals does not differ
from that of patients with an idiopathic dilated cardiomy-
opathy (3).
In the general population of cardiac patients, measures of
ventricular systolic performance, particularly the ejection
fraction, are powerful predictors of long-term outcome. In
patients with chronic heart failure, however, the range of
values far left vemricular function is relatively constricted
(that is, most patients have a left ventricular ejection fraction
<40%); consequently, indexes of cardiac performance have
substantially less predictive power . Nonetheless, patients
with the most compromised left ventricular function (as
evidenced by an ejection fraction <20%, a stroke work index
013540971Og/f3 .50
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<30g-mime or a left ventricular filling pressure >30 mm Hg)
have the most unfavorable long-term prognosis
(2) .
Some
workers (9,10) have suggested that indexes of right eentric-
ular function also provide independent prognostic informa-
tion, but this has not been the case in other studies (3,11)
.
Exercise capacity, especially when it is severely im-
paired, is a powerful predictor of the long-term outcome of
patients with chronic heart failure that is independent of the
severity of cardiac dysfunction (I) . This observation is
consistent with previous reports that exercise tolerance and
ventricular function are not closely related (1,5) and it
suggests that factors other than cardiac function must be
important in determining the delivery of oxygen to and the
utilization of oxygen by the peripheral organs, particularly
by exercising muscles (6) . We have shown (12,13) that
skeletal muscle metabolism differs markedly among patients
with heart failure and may be an independent determinant of
exercise capacity. Such differences in the peripheral adap-
tation to cardiac dysfunction occur not only in the skeletal
muscles but also in other organs (for example, the kidneys
and potentially the myocardium itself). The variability in the
peripheral adaptation to a decline in cardiac performance
determines the clinical presentation of patients with chronic
hear[ failure and may have important effects on prognosis .
The frequency and complexity of ventricular arrhythmias
are important predictors of mortality in patients with chronic
heart faihoe ( 14). High grade ventricular arrhythmias are
ubiquitous in these patients ; >70% have complex ventricular
ectopie activity or nonsustained ventricular tachycardia .
Although the frequency and complexity of these ventricular
arrhythmias are inversely related to the severity of left
ventricular dysfunction, many investigators have noted that
such arrhythmias carry an independent (and serious) prog-
nostic import
. Surprisingly, these arrhythmias appear to
have less predictive value for sudden death than for overall
cardiovascular mortality (14).
Finally, veurohormonal systems are activated to various
degrees
in many
patients
with congestive heart jailare
.
In
general, patients with high ciculating leveis of vasoactive
neurohormones have more severe or more rapidly progres-
sive heart failure, although this condition may not be re-
flected by hemodynamic measurements obtained at a single
point in lime . Such patients also usually require higher doses
of diuretics, have a greater reduction in regional blood flow
and exhibit more frequent and complex ventricular arrhyth-
mias than do patients with little evidence of neurohormonal
activity ( ;5-17). Hyponatremia has been recognized to he a
convenient indicator of increased circulating levels of neu-
rohormooes in patients with left ventricular dysfunction
(18,19)
. It is, therefore, not surprising that neurohormonal
activation (as measured by plasma norepinephrine, plasma
resin activity or serum sodium coucentmlion) is a poor
prognostic finding in patients with chronic heart failure
(15,17,19,20) .
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Modification of risk factors by treatment . Pharmacologic
interventions directed at modifying these prognostic factors
do not necessarily alter the survival of patients with chronic
heart failure . Positive inotropic drugs may (at least tempo-
rarily) reduce symptoms and improve ventricular function
and exercise tolerance without reducing mortality (21) ; anti-
arrhythmic drugs may abolish ventricular arrhythmias with-
out prolonging life (14) . A causal relation may exist, how-
ever, between neurohormonal activity and survival in heart
failure . Several trials (22-25) suggest that drugs that interfere
with the sympathetic nervous system (beta-blockers) and the
renin-angiotensin system (converting enzyme inhibitors)
may reduce mortality in patients with chronic heart failure .
Both types of intervention can improve left ventricular
performance (26,27) and reduce the frequency and complex-
ity of ventricular arrhythmias (28,29), and both types may
reduce the incidence of sudden and nonsudden deaths . A
reduction in sudden death was the principal manifestation of
benefit in the Captopril Multicenter Study (30) and the
Beta-Blocker Heart Attack Trial (31), whereas a reduction in
death from progressive heart failure was the principal per-
ceived mechanism of mortality reduction in the CONSEN-
SUS study (24) . These observations suggest that neurohor-
monal activation is directly deleterious to the survival of
patients with chronic heart failure
.
The findings of another survival trial, the Vasodilator
Heart Failure Trial (V-HerT) (32), however, raise doubts
about the importance of neurohormonal activation in deter-
mining survival in chronic heart failure . In that study, a
combination of direct-acting vasodilators (hydralazine and
isosorbide dinitrate) reduced mortality in patients with mild
to moderate heart failure, but these agents do not suppress
neurohormonal activity and may further increase it (33) The
most probable mechanism by which direct-acting vasodila-
tors could have prolonged life in this study is by retarding the
rate of disease progression by ameliorating loading condi-
tions in the failing heart. Indeed, patients who exhibited an
improvement in left ventricular function in V-HeFT were
most likely to experience a reduction in mortality (4) .
Because experimental and clinical observations also indicate
that converting enzyme inhibitors (and perhaps beta-
blockers) also exert beneficial effects on cardiac perfor-
mance (23,27,34), it is possible that improved left ventricular
function is the common mechanism by which pharmacologic
interventions prolong survival in chronic heart failure . Alter-
natively, some of the patients treated with direct-acting
vasodilators in V-HeFT may have experienced a reduction
in neurohormonal activity as a consequence of improved
cardiac performance and these patients may have experi-
enced the most marked reduction in mortality
. Subset anal-
ysis of completed studies and the results of ongoing trials,
such as V-HeFr tI (which compares the combination of
hydralazine and isosorbide dinitrate with a converting-
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enzyme inhibitor), may distinguish between these possibili-
ties and elucidate the mechanism of prolonged survival,
Clinical Status and Symptoms
Although a reduction in mortality is an important goal in
the long-term treatment of patients with chronic heart fail-
ure, it is equally desirable to ameliorate the symptoms and
improve the functional status of these patients for the
duration of their lives. The long-term outcome of patients
cannot be considered to be satisfactory if life is prolonged
but remains extremely limited . Treatment must be directed
at improving the patient's work capacity and self-sufficiency
as well as reducing the need for increments in medication
and physician and hospital visits .
Neurohormonal activity and clinical status. Does neuro-
hormonal activity play a unique tole in determining the
elinieal status of patients with chronic heart failure? Activa-
tion of the sympathetic nervous system and the renin-
angiotensin system may exacerbate clinical symptoms not
only by enhancing the peripheral vasoconstriction that is
seen in this disorder, but also by causing changes in sodium
and water balance, renal blood flow and myocardial metab-
olism that may contribute importantly to the symptoms and
exercise intolerance of these patients. If these additional
effects of the activated neurohormonal systems are impor-
tant in determining the clinical status of patients with chronic
heart failure, we might expect neurohormonal antagonists to
produce long-term symptomatic benefits that would not be
seen during treatment with direct-acting vasodilator drugs .
Numerous studies appear to support such a unique role
for neurohormotal activation in the pathogenesis of the
symptoms of heart failure, Neurohormonal antagonists (par-
ticularly the converting enzyme inhibitors) have proved to
be superior to direct-acting vasodilators in their ability to
ameliorate the symptoms of heart failure and reduce the
need for additional drugs, hospital stays and emergency
room visits . These benefits of converting enzyme inhibitors
have been demonstrated in controlled studies
of short dura-
tion (=3 months) (27,28 .35) and long duration (-6 months)
(24 .36,37) and in patients with mild, moderate and severe
symptoms (24,33-35) In contrast, direct-acting vasodilators
produce inconsistent relief of symptoms and minimal
changes in exercise tolerance (38,39), even though these
agents lend to produce more dramatic hemodynamic effects
than do drugs that interfere with neurohormonal activity . In
V-HeFT (40),
the combination of hydralazine and isosorbide
dinitrate that reduced mortality and improved survival pro-
duced minimal change in symptoms or in exercise capacity .
These findings suggest that neurohormonal activation may
play an important role in determining the short- and long-
term clinical status of patients with chronic heart failure .
Conclusions- Neurohormonal activation appears to paral-
lel the severity of heart failure, whether the syndrome is
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assessed according to symptoms or prognosis . Does this
neurohormonal activity contribute directly to the exercise
intolerance and high mortality of these patients or is it simply
a marker of the severity of the underlying disease? If
neurohormonal activity plays a pathogenetic role in the
lung-term outcome of these patients independent
of
its
effect, on the peripheral vasculature, then neurohormonal
antagonists should provide symptomatic and prognostic ben-
efits above those seen with direct-acting -tasodilators . The
present analysis suggests that neurohormonal antagonists
may indeed exert unique benefits with respect to the long-
term functional status of patients with chronic heart failure,
but future direct comparisons between neurohormonal an-
tagonists and direct-acting vasodilators (coupled with mea-
surements of neurohormonal activity) will be needed to
address this question with respect to survival .
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Congestive heart failure is a progressive disorder in which
the hemodynamic and symptomatic status of affected pa-
tients deteriorates over a period of months to years, even in
the absence of clinically apparent intercurrent events
. De-
spite extensive characterization of the biochemical and
physiologic abnormalities in this disease, the cause of this
progressive decline in ventricular performance remains un-
known . Some observers have suggested that myocardial
function deteriorates in chronic heart failure as a conse-
gttence of the cumulative damage that might be expected to
follow any prolonged hemodynamic stress . According to this
concept, any increase in left ventricular dimensions and wall
stress leads to excessive energy utilization by the failing
heart, which in turn leads (in some fashion) to a loss of viable
myocardium . Although attractive, this hypothesis remains
speculative ; the lack of supporting evidence suggests that
alternative possibilities should be explored . In this regard it
is noteworthy that the neurohormonal systems that are
activated in chronic heart failure have physiologic actions
that are deleterious to myocardial function ; such activation
offers an appealing explanation for the progressive deterio-
